Trials / Unknown
UnknownNCT05068921
A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy
Phase I Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A phase I clinical trial of tolerability and pharmacokinetics of TQB2858 injection in subjects with advanced malignancy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2858 injection | TQB2858 is an anti-programmed death ligand 1（PD-L1）/transforming growth factor-β （TGF-β） bi-functional fusion protein. |
Timeline
- Start date
- 2021-12-09
- Primary completion
- 2023-05-01
- Completion
- 2023-07-01
- First posted
- 2021-10-06
- Last updated
- 2021-12-13
Locations
17 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05068921. Inclusion in this directory is not an endorsement.